Maria R. Baer

23.4k total citations · 1 hit paper
393 papers, 11.6k citations indexed

About

Maria R. Baer is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Maria R. Baer has authored 393 papers receiving a total of 11.6k indexed citations (citations by other indexed papers that have themselves been cited), including 274 papers in Hematology, 141 papers in Molecular Biology and 111 papers in Genetics. Recurrent topics in Maria R. Baer's work include Acute Myeloid Leukemia Research (221 papers), Chronic Myeloid Leukemia Treatments (91 papers) and Acute Lymphoblastic Leukemia research (76 papers). Maria R. Baer is often cited by papers focused on Acute Myeloid Leukemia Research (221 papers), Chronic Myeloid Leukemia Treatments (91 papers) and Acute Lymphoblastic Leukemia research (76 papers). Maria R. Baer collaborates with scholars based in United States, France and Germany. Maria R. Baer's co-authors include Clara D. Bloomfield, Meir Wetzler, Kieran L. O’Loughlin, Hans Minderman, Richard A. Larson, Bayard L. Powell, Andrew J. Carroll, Krzysztof Mrózek, Karthika Natarajan and Jonathan E. Kolitz and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Maria R. Baer

386 papers receiving 11.3k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

2010 548 citations Guido Marcucci, Kati Maharry et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maria R. Baer United States	54	6.3k	5.3k	3.6k	2.3k	1.8k	393	11.6k
Meir Wetzler United States	48	5.0k 0.8×	3.0k 0.6×	2.1k 0.6×	2.1k 0.9×	1.9k 1.0×	245	8.6k
Tapan M. Kadia United States	57	9.8k 1.5×	5.4k 1.0×	2.7k 0.7×	3.9k 1.7×	3.0k 1.6×	778	13.2k
Roland B. Walter United States	53	6.7k 1.1×	3.7k 0.7×	3.2k 0.9×	1.4k 0.6×	2.2k 1.2×	365	11.0k
Courtney D. DiNardo United States	53	10.1k 1.6×	6.6k 1.2×	2.6k 0.7×	3.3k 1.5×	2.4k 1.3×	628	13.5k
Nigel H. Russell United Kingdom	57	8.9k 1.4×	4.4k 0.8×	3.3k 0.9×	2.5k 1.1×	2.5k 1.4×	355	12.4k
Elisabeth Paietta United States	61	7.8k 1.2×	4.7k 0.9×	3.0k 0.8×	2.6k 1.1×	4.3k 2.4×	278	12.9k
Selina M. Luger United States	47	5.4k 0.9×	2.9k 0.5×	2.9k 0.8×	1.1k 0.5×	3.2k 1.8×	304	9.7k
Christian Récher France	49	5.0k 0.8×	4.4k 0.8×	1.9k 0.5×	1.8k 0.8×	1.1k 0.6×	299	9.1k
Daniel J. DeAngelo United States	60	9.0k 1.4×	6.2k 1.2×	4.3k 1.2×	3.9k 1.7×	4.3k 2.4×	444	16.3k
Gautam Borthakur United States	65	13.2k 2.1×	6.7k 1.3×	2.9k 0.8×	6.5k 2.9×	3.3k 1.8×	809	17.7k

Countries citing papers authored by Maria R. Baer

Since Specialization

Citations

This map shows the geographic impact of Maria R. Baer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria R. Baer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria R. Baer more than expected).

Fields of papers citing papers by Maria R. Baer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria R. Baer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria R. Baer. The network helps show where Maria R. Baer may publish in the future.

Co-authorship network of co-authors of Maria R. Baer

This figure shows the co-authorship network connecting the top 25 collaborators of Maria R. Baer. A scholar is included among the top collaborators of Maria R. Baer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria R. Baer. Maria R. Baer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goloubeva, Olga, James F. Childress, Grace Li, et al.. (2024). Clinical outcomes of patients with acute myeloid leukemia and cardiovascular disease. Leukemia Research. 138. 107456–107456. 2 indexed citations

Oluwole, Olalekan O., Armin Ghobadi, Ryan D. Cassaday, et al.. (2024). Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.. Journal of Clinical Oncology. 42(16_suppl). 6531–6531. 3 indexed citations

Niyongere, Sandrine, et al.. (2024). Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation. Cancer Research Communications. 4(2). 431–445. 5 indexed citations

Koka, Rima, et al.. (2023). Fusion Gene-Based Classification of Variant Cytogenetic Rearrangements in Acute Myeloid Leukemia. Genes. 14(2). 396–396. 1 indexed citations

Mrózek, Krzysztof, Jessica Kohlschmidt, James S. Blachly, et al.. (2023). Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. Leukemia. 37(4). 788–798. 31 indexed citations

Bailey, Christopher M., Rena G. Lapidus, Sandrine Niyongere, et al.. (2021). PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition–Dependent GSK-3β–Mediated c-Myc and Pim-1 Proteasomal Degradation. Molecular Cancer Therapeutics. 20(4). 676–690. 17 indexed citations

Cortes, Jörge E., Justin M. Watts, Thomas Prébet, et al.. (2018). FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study. Blood. 132(Supplement 1). 1452–1452. 14 indexed citations

Natarajan, Karthika, Rena G. Lapidus, Rossana Trotta, et al.. (2017). Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation. Clinical Cancer Research. 24(1). 234–247. 36 indexed citations

Hedrich, William D., Jingwei Xiao, Scott Heyward, et al.. (2016). Activation of the Constitutive Androstane Receptor Increases the Therapeutic Index of CHOP in Lymphoma Treatment. Molecular Cancer Therapeutics. 15(3). 392–401. 17 indexed citations

10.

Muvarak, Nidal, Carine Robert, Maria R. Baer, et al.. (2015). c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase–Activated Leukemias. Molecular Cancer Research. 13(4). 699–712. 54 indexed citations

11.

Gojo, Ivana, Ming Tan, Hong‐Bin Fang, et al.. (2013). Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia. Clinical Cancer Research. 19(7). 1838–1851. 40 indexed citations

12.

Davidoff, Amy J., et al.. (2011). Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes. Haematologica. 97(1). 128–132. 13 indexed citations

13.

Becker, Heiko, Guido Marcucci, Kati Maharry, et al.. (2009). Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology. 28(4). 596–604. 241 indexed citations

14.

Xie, Yingqiu, Mehmet Burcu, & Maria R. Baer. (2009). The Serine/Threonine Kinase Pim-1 Stabilizes 130 Kilodalton FLT3 and Promotes Aberrant Signaling through STAT5 in Acute Myeloid Leukemia Cells with FLT3 Internal Tandem Duplication: Synergistic Apoptosis Induction by Pim-1 and FLT3 Inhibitors.. Blood. 114(22). 942–942. 3 indexed citations

15.

Link, Petra A., Maria R. Baer, Smitha R. James, David A. Jones, & Adam R. Karpf. (2008). p53-Inducible Ribonucleotide Reductase ( p53R2/RRM2B ) Is a DNA Hypomethylation–Independent Decitabine Gene Target That Correlates with Clinical Response in Myelodysplastic Syndrome/Acute Myelogenous Leukemia. Cancer Research. 68(22). 9358–9366. 44 indexed citations

16.

Pawarode, Attaphol, et al.. (2007). Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities. Leukemia Research. 31(11). 1589–1592. 7 indexed citations

17.

Minderman, Hans, Yunfei Zhou, Kieran L. O’Loughlin, & Maria R. Baer. (2006). Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. Cancer Chemotherapy and Pharmacology. 60(2). 245–255. 62 indexed citations

18.

Pawarode, Attaphol, Hans Minderman, Kieran L. O’Loughlin, William R. Greco, & Maria R. Baer. (2006). Rapamycin overcomes multidrug resistance (MDR) mediated by P-glycoprotein (Pgp), Multidrug Resistance Protein-1 (MRP-1), Breast Cancer Resistance Protein (BCRP) and Lung Resistance Protein (LRP) and synergizes with substrate drugs in MDR cells.. Cancer Research. 66. 1270–1270. 3 indexed citations

19.

Ojima, Iwao, Christopher P. Borella, Pierre‐Yves Bounaud, et al.. (2005). Design, Synthesis and Structure−Activity Relationships of Novel Taxane-Based Multidrug Resistance Reversal Agents. Journal of Medicinal Chemistry. 48(6). 2218–2228. 28 indexed citations

20.

Minderman, Hans, et al.. (2005). Downregulation of survivin expression by SN-38 is preceded by altered expression of regulatory factors of the NF-kappa-B (NFkB) transcription complex. Cancer Research. 65. 1269–1269. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact